Mid-stage MDS study of MEI Pharma's pracinostat to continue as planned; shares up 2% [Seeking Alpha]
MEI Pharma, Inc. (MEIP)
Last mei pharma, inc. earnings: 2/6 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.meipharma.com
Company Research
Source: Seeking Alpha
Mid-stage MDS study of MEI Pharma's pracinostat to continue as planned; shares up 2%Based on the outcome of a planned interim analysis, the open-labelPhase 2 study assessing MEI Pharma's (MEIP+2.4%) pracinostat plus azacitidine (Celgene's VIDAZA) in higher-risk myelodysplastic syndrome (MDS) patients willcontinue as planned.The specific threshold for continuation was patient retention. At data cutoff, 10% of patients discontinued treatment due to adverse events in the first three cycles of therapy, a rate consistent with azacitidine alone. Enrollment will now be expanded to 60 MDS patients.According to ClinicalTrials.gov, the estimated completion date is June 2020.MEI out-licensed pracinostat, an oral histone deacetylase inhibitor, to Swiss drug maker Helsinn in August 2016. Helsinn is primarily responsible for development and commercialization costs.See all stocks on the move »Now read:MEI Pharma Is Worth A Look As A Speculative Play After Big $75 Million Cash Influx »
Show less
Read more
Impact Snapshot
Event Time:
MEIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MEIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MEIP alerts
High impacting MEI Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
MEIP
News
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.MarketBeat
- MEI Pharma, Inc. (NASDAQ: MEIP) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $7.00 price target on the stock.MarketBeat
- MEI Pharma shelves plans for a second return of capital [Seeking Alpha]Seeking Alpha
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients [Yahoo! Finance]Yahoo! Finance
MEIP
Earnings
- 2/13/24 - Miss
MEIP
Sec Filings
- 2/29/24 - Form EFFECT
- 2/28/24 - Form 424B5
- 2/21/24 - Form 8-K
- MEIP's page on the SEC website